Stephen P Juraschek1, Edgar R Miller, Allan C Gelber. 1. Johns Hopkins Bloomberg School of Public Health, Welch Center for Prevention, Epidemiology and Clinical Research, and Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.
Abstract
OBJECTIVE: To determine the association and prevalence of gout among overweight, obese, and morbidly obese segments of the US population. METHODS: Among participants (age ≥20 years) of the National Health and Nutrition Examination Surveys in 1988-1994 and 2007-2010, gout status was ascertained by self-report of a physician diagnosis. Body mass index (BMI) was examined in categories of <18.5 kg/m(2) , 18.5-24.9 kg/m(2) , 25-29.9 kg/m(2) , 30-34.9 kg/m(2) , and ≥35 kg/m(2) and as a continuous variable. The cross-sectional association of BMI category with gout status was adjusted for demographic and obesity-related medical disorders. RESULTS: In the US, the crude prevalence of gout was 1-2% among participants with a normal BMI (18.5-24.9 kg/m(2) ), 3% among overweight participants, 4-5% with class I obesity, and 5-7% with class II or class III obesity. The adjusted prevalence ratio comparing the highest to a normal BMI category was 2.46 (95% confidence interval [95% CI] 1.44-4.21) in 1988-1994 and 2.21 (95% CI 1.50-3.26) in 2007-2010. Notably, there was a progressively greater prevalence ratio of gout associated with successively higher categories of BMI. In both survey periods, for an average American adult standing 1.76 meters (5 feet 9 inches), a 1-unit higher BMI, corresponding to 3.1 kg (~6.8 pounds) greater weight, was associated with a 5% greater prevalence of gout, even after adjusting for serum uric acid (P < 0.001). CONCLUSION: Health care providers should be aware of the elevated burden of gout among both overweight and obese adults, applicable to both women and men, and observed among non-Hispanic whites, non-Hispanic African Americans, and Mexican Americans in the US.
OBJECTIVE: To determine the association and prevalence of gout among overweight, obese, and morbidly obese segments of the US population. METHODS: Among participants (age ≥20 years) of the National Health and Nutrition Examination Surveys in 1988-1994 and 2007-2010, gout status was ascertained by self-report of a physician diagnosis. Body mass index (BMI) was examined in categories of <18.5 kg/m(2) , 18.5-24.9 kg/m(2) , 25-29.9 kg/m(2) , 30-34.9 kg/m(2) , and ≥35 kg/m(2) and as a continuous variable. The cross-sectional association of BMI category with gout status was adjusted for demographic and obesity-related medical disorders. RESULTS: In the US, the crude prevalence of gout was 1-2% among participants with a normal BMI (18.5-24.9 kg/m(2) ), 3% among overweight participants, 4-5% with class I obesity, and 5-7% with class II or class III obesity. The adjusted prevalence ratio comparing the highest to a normal BMI category was 2.46 (95% confidence interval [95% CI] 1.44-4.21) in 1988-1994 and 2.21 (95% CI 1.50-3.26) in 2007-2010. Notably, there was a progressively greater prevalence ratio of gout associated with successively higher categories of BMI. In both survey periods, for an average American adult standing 1.76 meters (5 feet 9 inches), a 1-unit higher BMI, corresponding to 3.1 kg (~6.8 pounds) greater weight, was associated with a 5% greater prevalence of gout, even after adjusting for serum uric acid (P < 0.001). CONCLUSION: Health care providers should be aware of the elevated burden of gout among both overweight and obese adults, applicable to both women and men, and observed among non-Hispanic whites, non-Hispanic African Americans, and Mexican Americans in the US.
Authors: Mara A McAdams; Janet W Maynard; Alan N Baer; Anna Köttgen; Sandra Clipp; Josef Coresh; Allan C Gelber Journal: J Rheumatol Date: 2010-12-01 Impact factor: 4.666
Authors: Stuart P Weisberg; Daniel McCann; Manisha Desai; Michael Rosenbaum; Rudolph L Leibel; Anthony W Ferrante Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: A-K Tausche; M Christoph; M Forkmann; U Richter; S Kopprasch; C Bielitz; M Aringer; C Wunderlich Journal: Rheumatol Int Date: 2013-09-12 Impact factor: 2.631
Authors: Janet W Maynard; Mara A McAdams-DeMarco; Andrew Law; Linda Kao; Allan C Gelber; Josef Coresh; Alan N Baer Journal: Am J Epidemiol Date: 2013-12-13 Impact factor: 4.897
Authors: Bridget Teevan Burke; Anna Köttgen; Andrew Law; Beverly Gwen Windham; Dorry Segev; Alan N Baer; Josef Coresh; Mara A McAdams-DeMarco Journal: Arthritis Care Res (Hoboken) Date: 2015-12 Impact factor: 4.794
Authors: M Gleimer; Y Li; L Chang; S Paczesny; D A Hanauer; D G Frame; C A Byersdorfer; P R Reddy; T M Braun; S W Choi Journal: Bone Marrow Transplant Date: 2014-12-22 Impact factor: 5.483
Authors: Stephen P Juraschek; Allan C Gelber; Hyon K Choi; Lawrence J Appel; Edgar R Miller Journal: Arthritis Rheumatol Date: 2016-12 Impact factor: 10.995
Authors: Hailey N Miller; Jeanne Charleston; Beiwen Wu; Kelly Gleason; Karen White; Cheryl R Dennison Himmelfarb; Daniel E Ford; Timothy B Plante; Allan C Gelber; Lawrence J Appel; Edgar R Miller; Stephen P Juraschek Journal: Clin Trials Date: 2020-09-15 Impact factor: 2.486